Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Perrigo Company PLC (NYSE:PRGO)

68.43
Delayed Data
As of Mar 22
 +0.29 / +0.43%
Today’s Change
67.08
Today|||52-Week Range
133.93
-17.78%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$9.8B

Company Description

Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences. The CHC segment includes the company's former segments, which are the Nutritionals and Israel Pharmaceuticals and Diagnostics business. The BCH segment consists of the Omega business. The Prescription Pharmaceuticals includes the Rx Pharmaceuticals business. The Specialty Sciences segment comprises of the assets, which focuses on the treatment of multiple sclerosis. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Contact Information

Perrigo Co. Plc
Treasury Building
Dublin Dublin 2
P:(531) 709-4000
Investor Relations:
(269) 686-3373

Employees

Shareholders

Individual stakeholders4.48%
Other institutional38.91%
Mutual fund holders36.45%

Top Executives

John T. HendricksonChief Executive Officer & Director
Ron L. WinowieckiChief Financial Officer
Thomas FarringtonChief Information Officer & Executive VP
Grainne QuinnChief Medical Officer & Executive Vice President
Todd W. KingmaSecretary, Executive VP & General Counsel